Service expected to offer insights to sponsors conducting clinical trials in any indication in under ten days.
Phesi, a patient-centric data software and service provider, has officially launched its new health check and trial rescue service. The service works by leveraging Phesi’s AI-driven trial accelerator platform to assess protocols in terms of patient view, country view, site view and investigator view. Reportedly, the free of charge service will enable sponsors to submit their protocols to Phesi for a review, offering real-time insights and forecasting within ten working days.
“The clinical trials industry is facing a chronic challenge,” stated Gen Li, PhD, CEO, founder, Phesi. “Once a trial is underway, sponsors are often forced to amend the protocol to better align with the targeted patient population, often with millions of dollars on the line. Further, we know around a fifth of trials designed today will fail and that many “zombie” trials continue to run, mostly caused by inadequate protocol design. Phesi’s new Health Check and Trial Rescue Service addresses these issues by conquering two evergreen challenges: too many protocol amendments and too many failures to complete enrolment as planned. With this service, sponsors can take a proactive, data-driven approach – they won’t need to wait until a study is at risk of failing before they take action.”
Reference: Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster. PharmiWeb. October 13, 2023. Accessed October 13, 2023. https://www.pharmiweb.com/press-release/2023-10-13/phesi-launches-health-check-and-trial-rescue-service-to-save-at-risk-trials-and-bring-drugs-to-market-faster#:~:text=Phesi's%20Health%20Check%20and%20Trial,trial%20planning%20and%20execution%20process
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.